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Abstract The therapeutic strategy for bilateral Wilms
tumor (WT) remains a challenge. Especially in cases with
chemotherapy resistant disease, bilateral nephrectomy is
sometimes inevitable. For optimal cure rates stage V WT
patients beneWt from adjuvant treatment; however, there are
limited data available on chemotherapy pharmacokinetics
in anephric children. In this report, we describe a 10-month
old girl with bilateral Wilms tumor and a novel germline
WT1 gene mutation. This patient hardly showed any
response on preoperative chemotherapy, and ultimately,
underwent sequential bilateral tumor-nephrectomy. Subse-
quently, during peritoneal dialysis, she received topotecan
as adjuvant chemotherapy based on plasma levels, indicat-
ing that this is a reasonable option as adjuvant treatment in
therapy-resistant Wilms tumor patients after bilateral
nephrectomy. This case showed a novel germline WT1 gene
mutation of which the correlation with resistant phenotype
has to be conWrmed in larger cohorts of WT patients.
Keywords Bilateral Wilms tumor · Topotecan · Anephric 
infant · Therapy resistance · Novel WT1 mutation
Introduction
Nephroblastoma, or Wilms tumor, is the most common
renal neoplasm of childhood, with an incidence of 1 in
10,000 children. The mean age of diagnosis is 42–47 months
for unilateral disease and 30–33 months for bilateral
disease [25]. Bilateral (stage V) tumors occur in approxi-
mately 5–6% of all Wilms tumors. The overall survival rate
is 90% for unilateral Wilms tumor and 80% for bilateral
disease. In cases with diVuse anaplasia, which occurs in
10% of all bilateral cases detected by initial diagnosis,
prognosis is even worse [9, 28].
The treatment of bilateral Wilms tumor is focussed on
complete resection of the tumor, which is mandatory to guar-
antee optimal outcome. Meanwhile the maximal amount of
normal renal parenchyma needs to be preserved. In case of
progressive or nonresponsive disease, bilateral nephrectomy
is inevitable in selected patients. For optimal cure rates, these
children beneWt from chemotherapy, before as well as after
surgery. However, in anephric children, the management of
adjuvant chemotherapeutic treatment has not been well
described, illustrated by the fact that only scarce information
is available on dose adjustment of various cytostatic drugs in
case of renal failure in children [4, 5, 11, 13, 17, 21].
It is conceivable that bilateral Wilms tumor patients,
especially if it occurs at an early age of onset, may carry
R. T. Lugtenberg · M. M. van den Heuvel-Eibrink (&)
Department of Pediatric Hematology/Oncology, 
Erasmus MC-Sophia Children’s Hospital, Room Sp2568, 
P. O. Box 2060, 3000 CB Rotterdam, The Netherlands
e-mail: m.vandenheuvel@erasmusmc.nl
K. Cransberg
Department of Pediatric Nephrology, 
Erasmus MC-Sophia Children’s Hospital, 
Rotterdam, The Netherlands
W. J. Loos
Department of Medical Oncology, 
Laboratory of Translational Pharmacology, 
Erasmus MC-Daniel den Hoed Cancer Center, 
Rotterdam, The Netherlands
A. Wagner
Department of Clinical Genetics, 
Erasmus Medical Center, Rotterdam, The Netherlands
M. Alders
Department of Clinical Genetics, Academic Medical Center, 
University of Amsterdam, Amsterdam, The Netherlands123
1040 Cancer Chemother Pharmacol (2008) 62:1039–1044germline WT1 gene mutations more frequently as compared
to patients with unilateral Wilms tumor, although previous
studies report conXicting observations [19, 23, 24]. Consti-
tutional defects of the WT1 gene are involved in several
overlapping clinical phenotypes, including the WAGR syn-
drome (Wilms tumor, Aniridia, Genito-urinary malforma-
tions and mental Retardation), Denys-Drash and Beckwith
Widemann syndrome.
It has been suggested that certain germline WT1 gene
mutations are associated with a more resistant phenotype,
which in bilateral cases harbors a higher risk for an even-
tual anephric status [14, 26]. In this case report we describe
a 10-month-old African girl with chemotherapy un-respon-
sive bilateral Wilms tumor, with a novel germline WT1
gene splice site mutation in intron 6, who ultimately, under-
went sequential bilateral tumor-nephrectomy. Subse-
quently, she received topotecan as adjuvant chemotherapy
in adjusted doses, based on the plasma levels, during perito-
neal dialysis.
Case
A 10-month-old African girl presented with a palpable
abdominal mass, without hematuria, and without abdomi-
nal pain. Medical history and development was unremark-
able. Physical examination showed neither dysmorphic
features nor congenital genitourinary abnormalities, nor
signs of hemihypertrophia. She had a normal tongue, iris
and external ears. Ultrasound of the abdomen showed nor-
mal uterus and ovaria. Cytogenetic analysis showed a nor-
mal female karyotype (46 XX). Ultrasound of the abdomen
showed a large tumor in the upper pole (largest diameter:
7.2 cm) and a smaller lesion in the middle pole (largest
diameter: 4 cm) of the left kidney. The right kidney
revealed a tumor in the upper pole (largest diameter: 3 cm)
and multiple small cysts, mostly centrally situated in the
kidney. No metastases in liver, lungs or abdominal lymph
nodes were found. MRI imaging revealed no nephrogenic
rests. Serum creatinine was normal for age.
Being diagnosed with bilateral renal tumor, she was
treated according to the stage V guidelines of the SIOP-
2001 protocol for renal tumors. She received weekly vin-
cristine (1 mg/m2) and dactinomycin (0.025 mg/kg) once
every 2 weeks. After 4 weeks, ultrasound showed hardly
any decrease in tumorsize in the left kidney, and a slight
growth on the right side, therefore doxorubicin (33 mg/m2)
was added to the vincristine/dactinomycin regimen (VAD).
After 9 weeks of chemotherapy, MRI of the abdomen
showed a change in radiological pattern suggesting
necrosis; however, again no change in size in any of the
tumors was found. Subsequently, surgery, including a left
tumor-nephrectomy and biopsy of the right kidney, was
performed. Pathology revealed vital triphasic nephroblas-
toma, (local stage I, in the left kidney), with less than 5%
necrosis after chemotherapy. Histology revealed no diVuse
anaplasia nor predominant blastema. Because of disap-
pointing response to VAD, postoperative treatment was
started, consisting of three cycles of etoposide (VP-16)
(300 mg/m2 for 3 consecutive days) and carboplatin
(400 mg/m2 for 3 consecutive days). Thereafter, again, no
tumor reduction was observed in the right kidney. Because
of the disappointing response and the central localisation of
the tumor, a second nephrectomy became inevitable.
Simultaneously a peritoneal dialysis catheter was inserted.
Histology again showed mixed type nephroblastoma, local
stage I, with no visible necrosis; no diVuse anaplasia nor
predominant blastema was found. Two days after the right
tumor-nephrectomy, peritoneal dialysis was started. With
the aim to treat the patient with adjuvant chemotherapy,
topotecan was started 2 weeks later. Two cycles of topo-
tecan were administered with an interval of 21 days, each
consisting of 5-day courses of daily infusions in modiWed
doses. Topotecan was administered intravenously in a daily
dose of 0.75 mg/m2 in 30 min and the course was followed
by G-CSF (neupogen) subcutaneously, 5 mg/kg daily.
Peripheral blood samples for topotecan pharmacokinetic
analysis were collected in lithium-heparinized tubes. On days
1 and 5, blood samples were collected before infusion,
15 min after the start of infusion, at the end of infusion, and
subsequently at 0.5, 1, 1.5, 2, 4, 8 and 12 h (only on day 1)
after the end of infusion. On days 2, 3 and 4, blood samples
were collected prior to infusion (i.e., trough level) and at the
end of infusion. All samples were processed within 15 min
after collection as described previously [13]. Peritoneal dial-
ysis samples were collected on day 1 and day 5 at 1, 2, 3, 4, 8
and 16 h after the start of infusion. Plasma as well as perito-
neal dialysate samples was stored at ¡20°C until analysis.
Determination of total topotecan levels (i.e., the sum of
lactone and carboxylate) in plasma was performed by high-
performance liquid chromatography with Xuorescence
detection, based on a previously described method with
minor modiWcations [20]. In brief, 100 l aliquots of
plasma were added to 300 l of cold (¡20°C) methanol.
After thorough vortex mixing, the samples were centri-
fuged for 5 min at 23,000£g. Aliquots of 100 l of the
clear supernatant were subsequently mixed with 400 l
0.1% acetic acid, from which 150 l was injected into the
HPLC system. Chromatographic separations were achieved
on a Hypersil BDS column (100 £ 3 mm ID, 3 m particle
size; Shandon, Cheshire, UK), which was maintained at
35°C. The mobile phase, composed of 10 mM potassium
dihydrogenphosphate–methanol–triethylamine (1,750:500:4,
v/v/v) with the pH adjusted to 6.0 (orthophosphoric acid),
was delivered at a Xow rate of 0.70 ml/min. The excitation
and emission wavelengths of the Jasco FP920 Xuorescence123
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respectively, with an emission bandwidth of 40 nm. Chro-
matographic data analysis was performed based on peak
height measurements relative to injected standards using
the ChromCard system of Fisons (Milan, Italy). Prior to
processing peritoneal dialysis samples were diluted twofold
in blank plasma, after which they were processed as
described above for plasma. Pharmacokinetic plasma
proWles of topotecan were analyzed by non-compartmental,
1/concentration weighted, analysis using the software
package WinNonlin version 5.0 (Pharsight, Mountain View,
CA, USA).
In this chemo-resistant case which needed neo-adjuvant
topotecan after bilateral tumornephrectomy, WT1 gene
analysis revealed a not previously described germline
mutation of the invariant nucleotides AG of the splice
acceptor site of intron 6, c.895-2A > G. The nucleotide
numbering is derived from the cDNA sequence
NM_024426.3 (isoform D, longest transcript), where the A
in the ATG initiation codon (base 401 in this sequence) cor-
responds to base 1. The parents did not carry this mutation,
indicating that this involves a de novo mutation. Analysis
of DNA extracted from tumor material showed that in the
tumor the normal wild type allele was lost (Fig. 1a).
To study the eVect of the splice site mutation in this
chemo-resistant case, RNA was extracted from tumor
material using RNABee (AMS Biotechnology). Reverse
transcription was done using SuperscriptIII and random
hexamers, and subsequent PCR was performed with prim-
ers speciWc for exon 4 and exon 8 of the WT1 gene. Two
diVerent products were ampliWed representing the normal
splice variants with and without exon 5 (data not shown).
Both products lacked exon 7 showing that the mutation
causes skipping of exon 7 (Fig. 1b). This results in a frame-
shift at position 299 of the WT1 protein and a truncation
after 31 altered aminoacids (p.Asp299fsX32).
Currently, after a follow-up of 32 months, the girl is in
Wrst complete continuous remission, in good health on peri-
toneal dialysis, waiting for renal transplantation.
Discussion
Although synchronous bilateral Wilms tumors have an
overall survival rate of 80%, the optimal therapeutic strat-
egy remains a challenge [9, 28]. Complete tumorresection,
while preserving a suYcient amount of normal renal
parenchyma, is not always feasible. Preoperative chemo-
therapy has been proven to be eVective in most bilateral
Wilms tumors; however, some patients show progressive
or nonresponsive disease (PRND) during preoperative
treatment.
Fig. 1 a Electropherograms 
showing the heterozygous muta-
tion c.895-2A > G in the blood 
sample and loss of the wild type 
allele in the tumor sample. 
Patient is heterozygous for a 
common SNP (rs16754), which 
shows LOH in the tumor. 
b Electropherogram showing 
skipping of exon 7 in the cDNA 
synthesised from tumor RNA123
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lines of the SIOP-2001 protocol for renal tumors. Because
of response failure following all preoperative standard che-
motherapeutic schedules, it was decided to perform sequen-
tial tumor-nephrectomies. The relatively favorable
histology in our patient encouraged us to follow this
delayed surgery strategy [9]. In general, to reach optimal
outcome, patients with Wilms tumors beneWt from adjuvant
chemotherapy and sometimes radiotherapy. In this (local
stage I) case radiotherapy was not indicated, as histology
was favorable. Moreover, the perspective of future kidney
transplantation discouraged us to use irradiation as adjuvant
treatment in this chemotherapy resistant case. Because of
resistance to Wrst and second-line chemotherapy and prom-
ising results with topotecan in phase I and II clinical trials
[21, 30] this camptothecin analogue was administered as
adjuvant treatment. Topotecan has shown to induce signiW-
cant growth inhibition in experimental Wilms tumors in
mouse models, even in very low doses [29]. Moreover, in
pediatric patients with recurrent Wilms tumor, Metzger
et al. [22] showed that topotecan was eVective, indicated as
responsive or stable disease in 18 of 25 children with favor-
able histology Wilms tumor, who were all pretreated with
other chemotherapeutic agents. However, it should be
noted that in this study, 12 of the 18 responders showed
earlier response to conventional chemotherapy.
Optimal chemotherapeutic treatment in anephric patients
is a challenge. So far, only a few reports discussing chemo-
therapy in anephric children are available [4, 13, 17, 21]. In
children with renal failure, it is questionable whether all
agents should be administered at reduced dosages [5]. In a
recent published report of the National Wilms Tumor Study
(NWTS) investigators concluded that dose reduction for
chemotherapeutic agents is not necessary for the treatment
of newly diagnosed Wilms tumor in children with renal
failure [5]. The included agents were vincristine, dactino-
mycin and doxorubicin. These agents can be safely admin-
istered in children with renal failure, because elimination of
these agents is barely achieved by renal excretion.
In patients with normal renal function, topotecan is
mainly eliminated by renal excretion, with approximately
half of the administered intravenous dose excreted as parent
drug in the urine [10]. Recently, pharmacokinetic studies in
patients with impaired renal function showed that reduction
of topotecan dosages in patients from 1.5 to 0.75 mg/m2
resulted in adequate topotecan levels [11]. Moreover, topo-
tecan was successfully administered in an anephric child at
a dose of 0.75 mg/m2 for 5 days in 30 min, with hemodialy-
sis on the second day and fourth day [13]. It was shown that
topotecan disposition was minimally aVected by hemodial-
ysis and was similar to that observed in children with
Wilms tumor, without renal failure. Likewise, in our patient
who was on peritoneal dialysis, the levels of topotecan in
plasma, after the administration of a reduced dose, were
comparable to the pharmacokinetic data of a previously
described anephric child [13]. As shown in Fig. 2a and
Table 1, topotecan pharmacokinetics on day 1 and day 5 are
comparable, illustrated by the minimal increases in the
trough levels before start of the infusion. During the infu-
sion, topotecan concentrations in peritoneal dialysate were
lower than those observed in plasma, while peak concentra-
tions in the dialysate were reached 1–4 h after the end of
infusion (Fig. 2b). This is consistent with an earlier publi-
cation in which it was shown that both pleural and ascites
represents only a small additional compartment for topo-
tecan distribution [6]. Although topotecan is eliminated by
peritoneal dialysis, as shown here, peritoneal dialysis is less
eVective than by the kidneys for the clearance of the drug.
Dose reductions of topotecan in patients on peritoneal dial-
ysis are thus required.
In our patient lack of chemotherapy response was found
concomitantly with the occurrence of a novel germline WT1
gene mutation. It is estimated that in at least 10% of all
Wilms tumor cases, the disease arises in children with clin-
ically well-deWned genetic conditions, including WAGR,
Denys–Drash, and Beckwith–Wiedemann syndrome [1, 3,
15, 18, 23, 27]. It has been suggested that nonsyndromic
Wilms tumor patients carry a higher risk of germline WT1
mutations in case of bilateral disease and an early age of
onset [24]. In contrast, Perotti et al. [23] concluded that
early age of diagnosis and bilaterality in Wilms tumor
patients without associated abnormalities are no eYcient
predictors of germline WT1 aberrations, based on a small
group of 20 tumors with only 9 bilateral tumors [23]. The
United Kingdom Children’s Cancer Group (UKCCG) ana-
lyzed 282 nonsyndromic WT patients and did not observe a
diVerence in frequency of germline WT1 mutations in uni-
lateral compared to bilateral Wilms tumor cases [19].
Therefore, it could be questioned whether all bilateral
Wilms tumors in nonsyndromic patients should be screened
on germline mutations of WT1, as we did in our patient.
Our patient revealed a germline splice site mutation in
Table 1 Summary of plasma pharmacokinetic data of topotecan
C Concentration, AUC area under the plasma concentration–time
curve, CL systemic clearance
a Concentration observed prior to start of infusion
b Calculated using data up to 12 h (day 1) and 8 h (day 5) after start of
infusion
Parameter Day 1 Day 2 Day 3 Day 4 Day 5
Cend of infusion (ng/ml) 24.8 29.2 28.5 16.2 38.3
Trough level (ng/ml)a – 0.82 1.53 2.03 2.23
AUC0–inf (ng/h per ml)b 176 – – – 207
CL (l/h per m2) 4.27 – – – 3.63
T1/2z (h) 3.62 – – – 3.22123
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been described in previous cases with Wilms tumor. This
mutation causes skipping of exon 7, which results in a
frameshift and premature truncation before the nuclear
localisation signal and the zinc Wngers. Unfortunately,
information is scarcely available about correlations
between germline mutations and outcome in Wilms tumor
patients [2, 7, 24, 26]. It seems that germline WT1 muta-
tions are associated with Wilms tumors of favorable histol-
ogy, illustrated by the fact that germline WT1 mutations are
found predominantly in Wilms tumors with stromal histol-
ogy [2, 7, 24, 26]. However, Schumacher et al. [26] found
that an extensive rhabdomyomatous diVerentiation and the
presence of WT1 mutations correlate with a tumor subtype
that responds poorly to chemotherapy. In our patient histol-
ogy was not unfavorable, but response after chemotherapy
was poor. Future studies in larger cohorts of patients are
necessary to reveal whether the novel WT1 gene mutation
in our patient is associated with histological subtype and
response.
More information is available on the association of
somatic WT1 gene mutations, which are found in approxi-
mately in 10% of all WT cases, and response, although con-
Xicting results have been published [7, 18, 33]. Loss of
heterozygosity (LOH) analysis revealed correlations
between allelic loss or gene ampliWcation and outcome in
Wilms tumor patients [8, 12, 16, 31, 32]. Grundy et al. [8]
found that loss of chromosome 1p and 16q are associated
with an adverse outcome. Loss of chromosome 11q and
22q and gain of 1q and monosomy 22 are associated with
an adverse outcome as well [12, 16, 32]. Our patient
revealed biallelic loss (one germline mutation and one LOH
in the tumor) of the WT1 gene. To determine the role of this
novel mutation studies in larger cohort of patients are nec-
essary.
In conclusion, our case shows that treatment with
reduced doses of topotecan may be a reasonable option as
adjuvant treatment in Wilms tumor patients, after bilateral
nephrectomy, following a failed response on the initially
started treatment. Further studies in larger cohorts of WT
patients are needed to gain more knowledge about the cor-
relation of this speciWc novel WT1 gene mutation with
response and prognosis.
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